ValiRx Strikes RNA Helicase Deal with McGill and IRICoR Under Asset-Focused Funding Model

ValiRx plc ( (GB:VAL) ) has issued an announcement.

ValiRx has signed a nine‑month evaluation and material transfer agreement with McGill University and Canadian non-profit IRICoR to assess a second-generation, orally available RNA helicase inhibitor, with its subsidiary Inaphaea Biolabs responsible for establishing target engagement and potency and owning the evaluation results. IRICoR will create a Canadian subsidiary, NewCo, to commercialise the evaluation results and background IP, with ValiRx having an option to license its results into NewCo for equity and potentially provide up to £2 million in staged seed funding alongside other investors, or alternatively receive a cash return of 1.5 times its evaluation investment if it elects not to proceed and the institutions later commercialise the technology; the structure is intended to attract external capital, advance a relatively late-stage oncology asset, and dilute risk at the asset level rather than at ValiRx plc, providing multiple routes to value creation for the company and its partners.

The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.40 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.

Spark’s Take on GB:VAL Stock

According to Spark, TipRanks’ AI Analyst, GB:VAL is a Neutral.

ValiRx plc’s overall stock score is primarily impacted by its challenging financial performance, characterized by significant losses and reliance on external financing. The technical analysis suggests a bearish trend, with some potential for upward movement. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.

To see Spark’s full report on GB:VAL stock, click here.

More about ValiRx plc

ValiRx plc is a UK-listed life sciences company specialising in early-stage cancer therapeutics and women’s health, providing scientific, financial and commercial frameworks to accelerate novel drug candidates from pre-clinical development to investor-ready assets. Through its wholly owned subsidiaries and collaborations, ValiRx selects, incubates and partners promising compounds, aiming to streamline and de-risk drug development before out-licensing or partnering lead candidates for further clinical advancement and commercialisation.

Average Trading Volume: 16,032,228

Technical Sentiment Signal: Sell

Current Market Cap: £3.08M

See more data about VAL stock on TipRanks’ Stock Analysis page.